Cencora (COR) saw a mixed bag of performance indicators over the past few quarters. The biotech company's stock fell due to temporary supply constraints of its anti-obesity drugs. However, it was also called out as a strong value and growth stock. Despite a revised outlook, the company continued to garner attention, securing a 'Moderate Buy' rating from brokerages. Walgreens Boots Alliance substantially sold off its shares of Cencora reaping millions in proceeds. The company also reported favorable Q3 results for fiscal year 2024 and made new EPS forecasts.Cencora saw an increase in stock value of 13.2% year-to-date, marked as a top momentum stock for the long term. Despite this, the company wasn’t exempt from hits and saw a 2.8% decrease since the last earnings report. Alongside performance reports, the company also announced governance and executive compensation structure enhancements, elected a new board member and revealed a data breach from earlier in the year. Cencora's Q3 earnings surpassed estimates, having revenue hits of $74.2B and an EPS of $2.42. Insider sale incidents including those by high-ranking executives sparked concerns over potential weakness. Looking forward, increased earnings estimates for the fiscal year 2024 hint at continued growth in the horizon.
Cencora COR News Analytics from Fri, 03 Nov 2023 07:00:00 GMT to Wed, 11 Sep 2024 14:00:25 GMT -
Rating -1
- Innovation 5
- Information 6
- Rumor -2
